ZA200108616B - A method for identifying pre-neoplastic and/or neoplastic states in mammals. - Google Patents
A method for identifying pre-neoplastic and/or neoplastic states in mammals. Download PDFInfo
- Publication number
- ZA200108616B ZA200108616B ZA200108616A ZA200108616A ZA200108616B ZA 200108616 B ZA200108616 B ZA 200108616B ZA 200108616 A ZA200108616 A ZA 200108616A ZA 200108616 A ZA200108616 A ZA 200108616A ZA 200108616 B ZA200108616 B ZA 200108616B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody reagent
- purinergic receptor
- specific
- tissue
- neoplastic
- Prior art date
Links
- 230000001855 preneoplastic effect Effects 0.000 title claims abstract description 21
- 241000124008 Mammalia Species 0.000 title claims abstract description 16
- 230000001613 neoplastic effect Effects 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 45
- 108010080192 Purinergic Receptors Proteins 0.000 claims abstract description 42
- 210000005170 neoplastic cell Anatomy 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 4
- 239000010839 body fluid Substances 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 41
- 102100037601 P2X purinoceptor 4 Human genes 0.000 claims description 38
- 241000282414 Homo sapiens Species 0.000 claims description 28
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims description 24
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims description 24
- 102000005962 receptors Human genes 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 238000001574 biopsy Methods 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 231100000504 carcinogenesis Toxicity 0.000 claims description 6
- 208000005623 Carcinogenesis Diseases 0.000 claims description 4
- 230000036952 cancer formation Effects 0.000 claims description 4
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims description 3
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims description 3
- 101710189967 P2X purinoceptor 4 Proteins 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000007398 colorimetric assay Methods 0.000 claims description 2
- 210000000416 exudates and transudate Anatomy 0.000 claims description 2
- 102100037603 P2X purinoceptor 5 Human genes 0.000 claims 3
- 101710189969 P2X purinoceptor 5 Proteins 0.000 claims 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 102000000033 Purinergic Receptors Human genes 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 59
- 238000002372 labelling Methods 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 28
- 241000700159 Rattus Species 0.000 description 28
- 206010060862 Prostate cancer Diseases 0.000 description 24
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 21
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 17
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 14
- 102100038358 Prostate-specific antigen Human genes 0.000 description 14
- 210000000981 epithelium Anatomy 0.000 description 14
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 12
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 12
- 238000001000 micrograph Methods 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 108091006146 Channels Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 230000030214 innervation Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001696 purinergic effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 108090000312 Calcium Channels Proteins 0.000 description 3
- 102000003922 Calcium Channels Human genes 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000633 nuclear envelope Anatomy 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- -1 potassium and sodium Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- 108010052178 teleocalcin Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LYLMANSTAHZWBY-UHFFFAOYSA-N 1-[6-(1-hydroxy-2,5-dioxopyrrolidin-3-yl)-6-oxohexyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)CCCCCN1C(=O)C=CC1=O LYLMANSTAHZWBY-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010005053 Bladder neck obstruction Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 101710189973 P2X purinoceptor 1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000053208 Porcellio laevis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 206010071019 Prostatic dysplasia Diseases 0.000 description 1
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 1
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000010222 extracellular calcium influx Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP9911A AUPP991199A0 (en) | 1999-04-21 | 1999-04-21 | Methods for diagnosing pre-cancerous and cancerous conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200108616B true ZA200108616B (en) | 2002-06-13 |
Family
ID=3814111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200108616A ZA200108616B (en) | 1999-04-21 | 2001-10-19 | A method for identifying pre-neoplastic and/or neoplastic states in mammals. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7183064B1 (de) |
| EP (1) | EP1179183B1 (de) |
| JP (1) | JP4633984B2 (de) |
| KR (1) | KR100819395B1 (de) |
| CN (1) | CN100557445C (de) |
| AT (1) | ATE456799T1 (de) |
| AU (2) | AUPP991199A0 (de) |
| CA (1) | CA2371163A1 (de) |
| DE (1) | DE60043775D1 (de) |
| DK (1) | DK1179183T3 (de) |
| ES (1) | ES2340137T3 (de) |
| HK (1) | HK1044190A1 (de) |
| NO (1) | NO331018B1 (de) |
| WO (1) | WO2001006259A1 (de) |
| ZA (1) | ZA200108616B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP991199A0 (en) * | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| AUPR201500A0 (en) * | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| ES2383712T3 (es) * | 2001-01-17 | 2012-06-25 | Biosceptre International Limited | Diagnóstico y tratamiento de cánceres y otras afecciones |
| US8067550B2 (en) | 2006-10-10 | 2011-11-29 | Biosceptre International Limited | Hybridomas producing antibodies against non functional P2X7 receptor |
| AU2013238152B2 (en) * | 2007-09-14 | 2015-09-24 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| AU2008299594B2 (en) | 2007-09-14 | 2013-10-03 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| ES2619681T3 (es) | 2007-09-14 | 2017-06-26 | Biosceptre (Aust) Pty Ltd | Novedosos epítopos P2X7 |
| KR101701300B1 (ko) | 2008-07-04 | 2017-02-01 | 바이오셉터 (어스트) 피티와이 엘티디 | 항ｐ２ｘ７ 펩티드 및 에피토프 |
| US9260508B2 (en) * | 2008-12-19 | 2016-02-16 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
| JP5936067B2 (ja) | 2009-08-20 | 2016-06-15 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 抗ｐ２ｘ７受容体抗体およびその断片 |
| EP3321285B1 (de) | 2009-12-24 | 2019-04-24 | Biosceptre (Aust) Pty Ltd | Antikörper gegen nichtfunktionelle oligomere p2x7-rezeptoren |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| AU2012278921B2 (en) | 2011-07-01 | 2016-11-10 | Biosceptre International Limited | Combination therapy |
| EP4001310A3 (de) * | 2014-05-02 | 2022-08-10 | MedImmune Limited | Ionenkanalmodulatoren und verwendungen davon |
| JP7127021B2 (ja) | 2016-10-21 | 2022-08-29 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 細胞傷害性粒子 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE920765A1 (en) * | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| JP3084982B2 (ja) * | 1992-11-25 | 2000-09-04 | 富士電機株式会社 | 半導体装置 |
| WO1995033048A2 (en) * | 1994-05-27 | 1995-12-07 | Glaxo Group Limited | P2x receptors (purinoceptor family) |
| CA2228999A1 (en) * | 1995-08-09 | 1997-02-20 | Institut National De La Sante Et De La Recherche Medicale | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis |
| WO1997041222A1 (en) | 1996-04-30 | 1997-11-06 | Smithkline Beecham P.L.C. | HUMAN P2x4 RECEPTOR SPLICE-VARIANTS |
| US6303338B1 (en) * | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| DE19829473C2 (de) * | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| AUPP991199A0 (en) * | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| AUPR201500A0 (en) * | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| ES2383712T3 (es) * | 2001-01-17 | 2012-06-25 | Biosceptre International Limited | Diagnóstico y tratamiento de cánceres y otras afecciones |
-
1999
- 1999-04-21 AU AUPP9911A patent/AUPP991199A0/en not_active Abandoned
-
2000
- 2000-04-26 US US10/019,356 patent/US7183064B1/en not_active Expired - Lifetime
- 2000-04-26 WO PCT/AU2000/000363 patent/WO2001006259A1/en not_active Application Discontinuation
- 2000-04-26 ES ES00918600T patent/ES2340137T3/es not_active Expired - Lifetime
- 2000-04-26 AU AU39490/00A patent/AU779845B2/en not_active Expired
- 2000-04-26 DK DK00918600.8T patent/DK1179183T3/da active
- 2000-04-26 EP EP00918600A patent/EP1179183B1/de not_active Expired - Lifetime
- 2000-04-26 CN CNB008090688A patent/CN100557445C/zh not_active Expired - Lifetime
- 2000-04-26 JP JP2001510845A patent/JP4633984B2/ja not_active Expired - Lifetime
- 2000-04-26 KR KR1020017013520A patent/KR100819395B1/ko active IP Right Grant
- 2000-04-26 AT AT00918600T patent/ATE456799T1/de active
- 2000-04-26 DE DE60043775T patent/DE60043775D1/de not_active Expired - Lifetime
- 2000-04-26 CA CA002371163A patent/CA2371163A1/en not_active Abandoned
-
2001
- 2001-10-19 ZA ZA200108616A patent/ZA200108616B/en unknown
- 2001-10-22 NO NO20015157A patent/NO331018B1/no not_active IP Right Cessation
-
2002
- 2002-08-09 HK HK02105830.1A patent/HK1044190A1/xx not_active IP Right Cessation
-
2006
- 2006-12-04 US US11/566,472 patent/US20070248963A1/en not_active Abandoned
-
2010
- 2010-09-09 US US12/878,865 patent/US20110111431A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO331018B1 (no) | 2011-09-12 |
| DE60043775D1 (de) | 2010-03-18 |
| AU3949000A (en) | 2001-02-05 |
| AU779845B2 (en) | 2005-02-17 |
| CN100557445C (zh) | 2009-11-04 |
| US20110111431A1 (en) | 2011-05-12 |
| ATE456799T1 (de) | 2010-02-15 |
| CN1355886A (zh) | 2002-06-26 |
| EP1179183B1 (de) | 2010-01-27 |
| EP1179183A4 (de) | 2003-01-22 |
| KR100819395B1 (ko) | 2008-04-04 |
| JP4633984B2 (ja) | 2011-02-16 |
| US7183064B1 (en) | 2007-02-27 |
| ES2340137T3 (es) | 2010-05-31 |
| EP1179183A1 (de) | 2002-02-13 |
| JP2003504643A (ja) | 2003-02-04 |
| WO2001006259A1 (en) | 2001-01-25 |
| DK1179183T3 (da) | 2010-05-25 |
| NO20015157L (no) | 2001-12-21 |
| AUPP991199A0 (en) | 1999-05-13 |
| CA2371163A1 (en) | 2001-01-25 |
| HK1044190A1 (en) | 2002-10-11 |
| KR20020022651A (ko) | 2002-03-27 |
| NO20015157D0 (no) | 2001-10-22 |
| US20070248963A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110111431A1 (en) | Method for identifying pre-neoplastic and/or neoplastic states in mammals | |
| US20080227122A1 (en) | P2y purinergic receptor expression for identifying preneoplastic and neoplastic states | |
| Krajewski et al. | Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma | |
| Pietras et al. | Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells | |
| JP5792121B2 (ja) | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 | |
| Matsuyama et al. | Estrogen receptor β is expressed in human stomach adenocarcinoma | |
| Andrews et al. | Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases | |
| US7767789B2 (en) | Truncated proteins as cancer markers | |
| Pruneri et al. | Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy | |
| Treszl et al. | Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma | |
| Mandalà et al. | Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients | |
| AU2002215689B2 (en) | P2Y purinergic receptor expression for identifying preneoplastic and neoplastic states | |
| AU2002215689A1 (en) | P2Y purinergic receptor expression for identifying preneoplastic and neoplastic states | |
| Asa et al. | Pathology of pituitary growth hormone excess | |
| Kunanuvat | The role of the relaxin receptor RXFP1 in brain cancer | |
| Blacoe-Masterson | Investigation of monoclonal antibodies raised to human ovarian carcinoma cell lines | |
| Chien | Role of calcitonin in prostate carcinomas | |
| Akhmedkhanov et al. | BIOLOGY–PROGNOSTIC FACTORS |